Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

SELL
$0.34 - $0.48 $5,519 - $7,792
-16,235 Reduced 99.39%
100 $0
Q1 2023

May 12, 2023

BUY
$0.39 - $0.65 $5,531 - $9,219
14,184 Added 659.41%
16,335 $6,000
Q4 2022

Feb 08, 2023

BUY
$0.44 - $131.17 $946 - $282,146
2,151 New
2,151 $1,000
Q1 2022

May 16, 2022

SELL
$0.92 - $1.94 $167 - $353
-182 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$1.04 - $2.12 $5,648 - $11,513
-5,431 Reduced 96.76%
182 $0
Q3 2021

Nov 15, 2021

BUY
$2.11 - $2.81 $3,949 - $5,260
1,872 Added 50.04%
5,613 $12,000
Q2 2021

Aug 13, 2021

SELL
$2.01 - $3.0 $50,183 - $74,901
-24,967 Reduced 86.97%
3,741 $10,000
Q1 2021

May 12, 2021

BUY
$2.09 - $5.11 $59,999 - $146,697
28,708 New
28,708 $86,000
Q3 2020

Nov 12, 2020

SELL
$1.75 - $8.19 $3,382 - $15,831
-1,933 Closed
0 $0
Q2 2020

Jul 31, 2020

BUY
$3.28 - $4.24 $5,270 - $6,813
1,607 Added 492.94%
1,933 $7,000
Q1 2020

May 01, 2020

SELL
$3.96 - $8.37 $7,421 - $15,685
-1,874 Reduced 85.18%
326 $1,000
Q4 2019

Feb 14, 2020

SELL
$4.56 - $7.45 $683 - $1,117
-150 Reduced 6.38%
2,200 $11,000
Q3 2019

Nov 14, 2019

BUY
$4.02 - $7.93 $9,446 - $18,635
2,350 New
2,350 $17,000
Q2 2019

Aug 14, 2019

SELL
$4.89 - $8.11 $11,173 - $18,531
-2,285 Closed
0 $0
Q1 2019

May 14, 2019

BUY
$3.67 - $5.5 $1,009 - $1,512
275 Added 13.68%
2,285 $12,000
Q4 2018

Feb 14, 2019

BUY
$3.64 - $7.12 $4,946 - $9,676
1,359 Added 208.76%
2,010 $7,000
Q3 2018

Nov 14, 2018

BUY
$6.95 - $11.64 $4,524 - $7,577
651 New
651 $5,000

Others Institutions Holding VCNX

About VACCINEX, INC.


  • Ticker VCNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,664,100
  • Market Cap $154M
  • Description
  • Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab,...
More about VCNX
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.